Missing the mark on prostate-specific antigen screening

JAMA. 2011 Dec 28;306(24):2719-20. doi: 10.1001/jama.2011.1879.
No abstract available

MeSH terms

  • Advisory Committees
  • Age Factors
  • Aged
  • Biopsy / adverse effects
  • Decision Making
  • Guidelines as Topic
  • Health Policy
  • Humans
  • Male
  • Mass Screening / standards*
  • Middle Aged
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / mortality
  • Survival Analysis
  • United States
  • Unnecessary Procedures

Substances

  • Prostate-Specific Antigen